Compare BCO & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCO | BLLN |
|---|---|---|
| Founded | 1859 | 2016 |
| Country | United States | United States |
| Employees | 125 | 713 |
| Industry | Oil Refining/Marketing | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.9B |
| IPO Year | 2009 | N/A |
| Metric | BCO | BLLN |
|---|---|---|
| Price | $97.63 | $109.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $154.00 | $126.71 |
| AVG Volume (30 Days) | 373.8K | ★ 758.2K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | ★ 29.20 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $3,562,300,000.00 | N/A |
| Revenue This Year | $7.22 | $46.29 |
| Revenue Next Year | $5.92 | $30.14 |
| P/E Ratio | $125.52 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $85.00 | $61.96 |
| 52 Week High | $136.37 | $138.70 |
| Indicator | BCO | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 35.62 | 61.91 |
| Support Level | N/A | $79.07 |
| Resistance Level | $117.36 | $138.70 |
| Average True Range (ATR) | 2.63 | 7.52 |
| MACD | -0.33 | 0.36 |
| Stochastic Oscillator | 15.65 | 91.68 |
The Brink's Co is a provider of secure logistics and security solutions for cash and other valuables. Its segments include: North America segment includes operations in the U.S. and Canada, including the Brink's Global Services (BGS) line of business; Latin America segment consists operations in Latin American countries where it has an ownership interest, including the BGS line of business; Europe segment includes total operations in European countries that provide services outside of the BGS line of business; and Rest of World segment consists operations in the Middle East, Africa and Asia. It also includes total operations in European countries that provide BGS services and BGS activity in Latin American countries. It derives maximum revenue from the North America segment.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.